The question that needs to be resolved is what exactly is happening in terms of product filing and why is Ranbaxy saying that the product filings have not been impacted, says Vikas Dandekar, India Bureau Chief, PharmAsiaNews.Com.
first published: Sep 16, 2013 11:16 am
A collection of the most-viewed Moneycontrol videos.
The Lawyer Renting in one of Mumbai’s most green societies | The Tenant
Live: Nifty extends gain for the third day, up nearly 2% this week | Closing Bell | 4K
From renewables to AI and SMEs: Madhusudan Kela on where he senses opportunity now
Will The Pre-Diwali Nifty Rally Rage On Amid Weak Global Cues? RIL Q2 in Focus | Opening Bell Live
You are already a Moneycontrol Pro user.